Clinical trial
Safety, Efficacy, and Mechanisms of Psilocybin-assisted Acceptance and Commitment Therapy (PACT) in Treating Major Depressive Disorder (MDD) Among Veterans
NCT07895134 is registered in ClinicalTrials.gov with VA Office of Research and Development as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety, Efficacy, and Mechanisms of Psilocybin-assisted Acceptance and Commitment Therapy (PACT) in Treating Major Depressive Disorder (MDD) Among Veterans
- Lead sponsor
- VA Office of Research and Development
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- January 1, 2027
- Completion date
- December 31, 2031
- Enrollment
- 150 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
major depression
Arms
As registered; 8 arms.
-
Psilocybin, modafanil, zolpidem, pimavanserin arm
Participants will receive a single dose of 1-30mg of psilocybin, in addition to 3 other drugs: modafinil, zolpidem, pimavanserin. All participants will be masked to the probability of being assigned to a specific arm
-
Psilocybin, modafanil, zolpidem arm
Participants will receive a single dose of 1-30mg of psilocybin, in addition to 2 other drugs: modafinil and zolpidem and placebo. All participants will be masked to the probability of being assigned to a specific arm
-
Psilocybin, modafanil, pimavanserin arm
Participants will receive a single dose of 1-30mg of psilocybin, in addition to 2 other drugs: modafinil, pimavanserin, and placebo. All participants will be masked to the probability of being assigned to a specific arm
-
Psilocybin, modafanil arm
Participants will receive a single dose of 1-30mg of psilocybin, in addition to 1 other drug: modafinil, and placebo. All participants will be masked to the probability of being assigned to a specific arm
-
Psilocybin, zolpidem, arm
Participants will receive a single dose of 1-30mg of psilocybin, in addition to 1 other drug: zolpidem, and placebo. All participants will be masked to the probability of being assigned to a specific arm
+3 more arms
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Hamilton Depression Rating Scale-6 (HAMD-6)
A clinician-administered, 6-item version of the Hamilton Depression Rating Scale that assesses core depressive symptoms including depressed mood, guilt, work and activities, psychomotor retardation, psychic anxiety, and somatic symptoms. Scores range from 0-22, with higher scores indicating greater depression severity. Administered at Baseline, Day 1, Day 7, Day 30, and Day 90.
Lead sponsor's other trials
VA Office of Research and Development, most recent start first.
+1,767 more trials See the organization page
Similar trials
Same condition (Major Depressive Disorder) and phase, most recent start first.
+396 more trials See the condition page